Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DISSECTING BRCA2

Financiado

Cerrado

Dissecting the role of BRCA2 in the DNA damage response and exploiting its parts...

Dissecting the role of BRCA2 in the DNA damage response and exploiting its parts for anticancer therapy Mutations in the tumor suppressor gene, BRCA2, cause susceptibility to breast and ovarian cancer. BRCA2 protein is required for homologous recombinational DNA repair (HRR), the predominant mechanism employed by cells to accurately... ver más

31/10/2015

INSTITUT CURIE FON...

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSTITUT CURIE FONDATION

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

DREMATURE DNA repair mechanisms and therapy resistance of BRCA2 defici... 187K€ Cerrado

BRCA INSIGHTS Understanding the functions of the BRCA protein complexes in... 2M€ Cerrado

SAF2014-59993-JIN CARACTERIZACION BIOQUIMICA, ESTRUCTURAL Y FUNCIONAL DEL SUPR... 204K€ Cerrado

BRCA2Interact Structural and biochemical characterization of pre recombina... 183K€ Cerrado

BRCA2complexes Structural and biochemical characterization of the BRCA2 bre... 231K€ Cerrado

OncIndLymph Oncogene induced DNA damage as driver of B cell lymphoma gen... 100K€ Cerrado

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Mutations in the tumor suppressor gene, BRCA2, cause susceptibility to breast and ovarian cancer. BRCA2 protein is required for homologous recombinational DNA repair (HRR), the predominant mechanism employed by cells to accurately repair DNA double-stranded breaks (DSBs). In humans, the central player of the HRR process is RAD51; it catalyzes the DNA strand exchange that results in the repaired DNA. Through its interaction with RAD51, BRCA2 controls RAD51 function by locating it to the DSBs. Thus, defects in BRCA2 lead to genomic instability, a hallmark of tumorigenesis. During my postdoc, I have revealed important aspects of BRCA2 protein, the regulatory function of the BRC repeats of BRCA2 on RAD51 DNA binding selectivity as well as contribute to the first biochemical characterization of the full-length BRCA2 protein. In an interdisciplinary approach and, as an independent researcher, my main goals are to: 1) Reveal new roles of BRCA2 by mapping the interactions with other proteins: For example, recently a DMC1 interacting site on BRCA2 has been reported involving BRCA2 in meiotic recombination. 2) Better understand the HRR process: Evidences from the BRCA2 homologue in fungus point to another DNA binding site in BRCA2; finding this region in the human protein may decipher important aspects of the regulation of HRR that remain elusive. 3) Exploit regions of the protein as a therapeutic tool for tumor treatment. We will use peptides derived from BRCA2 protein that are involved in interactions with key proteins in the HRR pathway to block this pathway in tumors cells. 4) Develop new strategies to carry these peptides to the targeted tumor cells. The combination of basic science (aims 1, 2) and applied science (aims 3, 4) approaches proposed here provides a framework to understand the connection between different DNA damage response mechanisms that in turn, will lead to develop new anticancer therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores